Search

EconomicsAnalysis

Moderna's Return to Profit Points to a Broader Bet on Cancer Vaccines

The biotech group has swung back into profit and remains the S&P 500's strongest performer, but the cancer vaccine case is still being built.

Faultline Desk · 2 hrs ago

EconomicsAnalysis

Pharma Boom: Eli Lilly Profits Soar

US drugmaker raises revenue outlook on strong demand

Faultline Desk · 29 Oct

EconomicsAnalysis

Repercussions of the Trump Administration's New Tariffs on Pharmaceuticals

A strategic analysis of how heightened tariffs on pharmaceuticals may reshape the global healthcare landscape.

Faultline Desk · 2 Apr